Quarterly report pursuant to Section 13 or 15(d)

Stock Incentive Plan

v3.21.2
Stock Incentive Plan
9 Months Ended
Sep. 30, 2021
Stock Incentive Plan  
Note 4. Stock Incentive Plan

Note 4 - Stock Incentive Plan

 

In April 2016, the Company’s Board of Directors and stockholders representing a majority of the Company’s outstanding stock at that time, approved the Monopar Therapeutics Inc. 2016 Stock Incentive Plan, as amended (the “Plan”), allowing the Company to grant up to an aggregate 700,000 shares of stock-based awards in the form of stock options, restricted stock units, stock appreciation rights and other stock-based awards to employees, non-employee directors and consultants. In October 2017, the Company’s Board of Directors voted to increase the stock award pool to 1,600,000 shares of common stock, which subsequently was approved by the Company’s stockholders. In April 2020, the Company’s Board of Directors voted to increase the stock award pool to 3,100,000 (an increase of 1,500,000 shares of common stock), which was approved by the Company’s stockholders in June 2020. In April 2021, the Company’s Board of Directors voted to approve an amendment to the 2016 Stock Incentive Plan to remove certain individual award limits and other provisions related to I.R.C. Section 162(m) and to update the limit on Incentive Stock Options to no more that 100% of the maximum aggregate number of shares which may be granted under the plan, which was approved by the Company’s stockholders in June 2021.

During the three months ended September 30, 2021, the Company’s Plan Administrator Committee (with regards to non-officer employees and consultants) and the Company’s Compensation Committee, as ratified by the Board of Directors (in the case of executive officers and non-employee directors), granted to one executive officer and one non-officer employee aggregate stock options for the purchase of 99,000 shares of the Company’s common stock with exercise prices ranging from $4.90 to $5.59 which vest over four years. All stock option grants have a 10-year term.

 

Under the Plan, the per share exercise price for the shares to be issued upon exercise of an option shall be determined by the Plan Administrator, except that the per share exercise price shall be no less than 100% of the fair market value per share on the grant date. Fair market value is the Company’s closing price on Nasdaq. Stock options generally expire after 10 years.

 

Stock option activity under the Plan was as follows:

 

 

 

Options Outstanding

 

 

 

Number of Shares Subject to Options

 

 

Weighted-Average Exercise Price

 

Balances at January 1, 2020

 

 

1,087,463

 

 

$ 2.94

 

Granted

 

 

174,357

 

 

 

14.08

 

Forfeited

 

 

(3,243 )

 

 

8.47

 

Balances at December 31, 2020

 

 

1,258,577

 

 

 

4.47

 

Granted(1)

 

 

400,476

 

 

 

6.29

 

Forfeited(2)

 

 

(17,906 )

 

 

9.33

 

Exercised

 

 

(2,913 )

 

 

6.00

 

Balances at September 30, 2021

 

 

1,638,234

 

 

 

4.86

 

Unvested options outstanding expected to vest (3)

 

 

408,473

 

 

 

7.40

 

 

(1)

400,476 options vest as follows: options to purchase 372,704 shares of the Company’s common stock vest 6/48ths on the six-month anniversary of grant date and 1/48th per month thereafter; options to purchase 17,772 shares of the Company’s common stock vest quarterly over one year; and options to purchase 10,000 shares of the Company’s common stock vest monthly over one year. Exercise prices range from $4.90 to $9.67 per share.

 

(2)

Forfeited options represent unvested shares and vested, expired shares related to employee terminations.

 

 

(3)

Estimated forfeitures only include known forfeitures to-date as the Company typically accounts for forfeitures as they occur due to a limited history of forfeitures.

 

A summary of options outstanding as of September 30, 2021, is shown below:

 

Exercise Prices

 

Number of Shares Subject to Options Outstanding

 

Weighted-Average

Remaining Contractual Term in Years

 

Number of Shares Subject to Options Fully Vested and Exercisable

 

Weighted-Average Remaining Contractual Term in Years

$0.001-$5.00

 

  564,920

 

5.04

 

  555,920

 

4.96

$5.01-$10.00

 

  916,957

 

7.95

 

  479,624

 

7.01

$10.01-$15.00

 

  145,232

 

8.34

 

  94,509

 

8.34

$15.01-$20.00

 

  11,125

 

8.31

 

  8,208

 

8.32

 

 

  1,638,234

 

6.98

 

  1,138,261

 

6.13

Restricted stock unit activity under the Plan was as follows:

 

 

 

Restricted Stock Units

 

 

Weighted-Average Grant Date Fair Value per Unit

 

Unvested balance at January 1, 2020

 

 

 

 

$

 

Granted

 

 

45,722

 

 

 

12.93

 

Vested

 

 

(5,156 )

 

 

12.93

 

Forfeited

 

 

(500 )

 

 

12.93

 

Unvested balance at January 1, 2021

 

 

40,066

 

 

 

12.93

 

Granted

 

 

124,374

 

 

 

6.81

 

Vested

 

 

(39,824 )

 

 

8.35

 

Forfeited

 

 

(1,843 )

 

 

8.06

 

Unvested Balance at September 30, 2021

 

 

122,773

 

 

 

8.29

 

 

During the three months ended September 30, 2021, and 2020, the Company recognized $140,501 and $163,807 of employee and non-employee director stock-based compensation expense as general and administrative expenses, respectively, and $241,263 and $102,346 as research and development expenses, respectively. During the nine months ended September 30, 2021, and 2020, the Company recognized $422,360 and $633,462, respectively, of employee and non-employee director stock-based compensation expense as general and administrative expenses and $664,630 and $303,415, respectively, as research and development expenses. The stock-based compensation expense is allocated on a departmental basis, based on the classification of the stock-based award holder. No income tax benefits have been recognized in the condensed consolidated statements of operations and comprehensive loss for stock-based compensation arrangements.

 

The Company recognizes as an expense the fair value of options granted to persons (currently consultants) who are neither employees nor non-employee directors. Stock-based compensation expense for consultants, recorded as research and development expense for the three months ended September 30, 2021, and 2020, was $10,300 and $17,560, respectively, and for the nine months ended September 30, 2021, and 2020, was $30,900 and $52,691, respectively.

 

The fair value of options granted from inception to September 30, 2021, was based on the Black-Scholes option-pricing model assuming the following factors: 4.7 to 6.2 years expected term, 55% to 85% volatility, 0.4% to 2.9% risk free interest rate and zero dividends. The expected term for options granted to-date was estimated using the simplified method.

 

Stock option grants and fair values under the Plan was as follows:

 

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stock options granted

 

 

99,000

 

 

 

7,000

 

 

 

400,476

 

 

 

174,357

 

Weighted-average grant date fair value per share

 

$ 3.96

 

 

$ 3.87

 

 

$ 4.48

 

 

$ 7.78

 

Fair value of shares vested

 

$ 280,883

 

 

$ 315,516

 

 

$ 838,901

 

 

$ 908,129

 

At September 30, 2021, the aggregate intrinsic value of outstanding vested stock options was approximately $2.7 million (unvested stock options had zero intrinsic value), and the weighted-average exercise price in aggregate was $4.86 which includes $3.88 for fully vested stock options and $7.40 for stock options expected to vest. At September 30, 2021, unamortized unvested balance of stock-based compensation was $2.9 million, to be amortized over 2.7 years.